Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 17/20 | 0.67 |
| ▸ | PPARD | Q03181 | 12/20 | 0.67 |
| ▸ | PPARG | P37231 | 6/20 | 0.67 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449884 | 0.89 | FFAR1 (0.64) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL3450254 | 0.85 | FFAR1 (0.61) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL3449993 | 0.82 | FFAR1 (0.62) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL3449394 | 0.77 | FFAR1 (0.65) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL3449360 | 0.75 | FFAR1 (0.61) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL28719063 | 0.75 | PPARD (0.64) | PPARDPPARA | |
| SCHEMBL3450989 | 0.74 | FFAR1 (0.70) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL5624535 | 0.74 | FFAR1 (0.64) | FFAR1PPARDPPARG | |
| SCHEMBL3451460 | 0.74 | FFAR1 (0.57) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL3452973 | 0.74 | FFAR1 (0.71) | FFAR1PPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20060258722-A1 | Condensed ring compound | TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258722-A1 | Condensed ring compound | GPR119, GLP1R, GCGR | FFAR1 93/4885PPARD 74/4885PPARG 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.